Literature DB >> 2874031

Effect of famotidine on oxidative drug metabolism.

K W Somerville, G A Kitchingman, M J Langman.   

Abstract

Famotidine, a new H2-receptor antagonist was tested for drug interactions using 14C-aminopyrine and antipyrine. Elimination of these model drugs was studied before and during 8 days of famotidine dosing in 8 healthy volunteers. Famotidine 40 mg b.d. did not inhibit aminopyrine 14CO2 half-life or antipyrine clearance although an unexpected mild enzyme inducing effect could not be excluded. It is unlikely that famotidine will inhibit hepatic drug metabolism during routine clinical use as the daily dose is expected to be 40 mg/day but interactions should be looked for if more prolonged or larger doses are used.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2874031     DOI: 10.1007/bf00541528

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  9 in total

1.  The estimation of antipyrine in biological materials.

Authors:  B B BRODIE; J AXELROD
Journal:  J Biol Chem       Date:  1949-05       Impact factor: 5.157

2.  Comparative effects of famotidine and cimetidine on antipyrine kinetics in healthy volunteers.

Authors:  C Staiger; B Korodnay; J X Devries; E Weber; P Müller; B Simon; H G Dammann
Journal:  Br J Clin Pharmacol       Date:  1984-07       Impact factor: 4.335

3.  The [14C]-aminopyrine breath test. A comparison of different forms of analysis.

Authors:  D A Henry; G Sharpe; S Chaplain; S Cartwright; G Kitchingman; G D Bell; M J Langman
Journal:  Br J Clin Pharmacol       Date:  1979-12       Impact factor: 4.335

4.  Effect of cimetidine on phenytoin serum levels.

Authors:  R B Salem; B D Breland; S K Mishra; J E Jordan
Journal:  Epilepsia       Date:  1983-06       Impact factor: 5.864

5.  Studies on MK-208 (YM-11170) a new, slowly dissociable H2-receptor antagonist.

Authors:  R G Pendleton; M L Torchiana; C Chung; P Cook; S Wiese; B V Clineschmidt
Journal:  Arch Int Pharmacodyn Ther       Date:  1983-11

6.  Effect of low-dose cimetidine on theophylline metabolism.

Authors:  C DeAngelis; S E Walker; W R Bartle
Journal:  Clin Pharm       Date:  1983 Nov-Dec

7.  Cimetidine: interaction with oral anticoagulants in man.

Authors:  M J Serlin; R G Sibeon; S Mossman; A M Breckenridge; J R Williams; J L Atwood; J M Willoughby
Journal:  Lancet       Date:  1979-08-18       Impact factor: 79.321

8.  Famotidine, a new, potent, long-acting histamine H2-receptor antagonist: comparison with cimetidine and ranitidine in the treatment of Zollinger-Ellison syndrome.

Authors:  J M Howard; A N Chremos; M J Collen; K E McArthur; J A Cherner; P N Maton; C A Ciarleglio; M J Cornelius; J D Gardner; R T Jensen
Journal:  Gastroenterology       Date:  1985-04       Impact factor: 22.682

9.  Cimetidine and ranitidine: comparison of effects on hepatic drug metabolism.

Authors:  D A Henry; I A Macdonald; G Kitchingman; G D Bell; M J Langman
Journal:  Br Med J       Date:  1980-09-20
  9 in total
  8 in total

Review 1.  Clinical pharmacokinetics of drugs used in the treatment of gastrointestinal diseases (Part II).

Authors:  K Lauritsen; L S Laursen; J Rask-Madsen
Journal:  Clin Pharmacokinet       Date:  1990-08       Impact factor: 6.447

Review 2.  Famotidine. An updated review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in peptic ulcer disease and other allied diseases.

Authors:  H D Langtry; S M Grant; K L Goa
Journal:  Drugs       Date:  1989-10       Impact factor: 9.546

3.  Influence of famotidine on verapamil pharmacokinetics in rats.

Authors:  Kamal M Matar
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2005 Jul-Sep       Impact factor: 2.441

Review 4.  Newer H2-receptor antagonists. Clinical pharmacokinetics and drug interaction potential.

Authors:  D R Krishna; U Klotz
Journal:  Clin Pharmacokinet       Date:  1988-10       Impact factor: 6.447

5.  Famotidine does not affect indocyanine green disposition and serum bile acid levels in healthy subjects.

Authors:  R Testa; A Grasso; F Dagnino; R Ibba; G Varagona; G Celle
Journal:  Br J Clin Pharmacol       Date:  1987-06       Impact factor: 4.335

6.  Famotidine and theophylline pharmacokinetics. An unexpected cimetidine-like interaction in patients with chronic obstructive pulmonary disease.

Authors:  R Dal Negro; C Pomari; P Turco
Journal:  Clin Pharmacokinet       Date:  1993-03       Impact factor: 6.447

Review 7.  Clinical pharmacokinetics of famotidine.

Authors:  H Echizen; T Ishizaki
Journal:  Clin Pharmacokinet       Date:  1991-09       Impact factor: 6.447

8.  Induction and quail liver diamine oxidase (histaminase). Part II: Different responses to the inducers.

Authors:  G Ignesti; F Buffoni; M Perretti; A Cintelli
Journal:  Agents Actions       Date:  1988-08
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.